24 / 26
Page 66
allied
academies
Archives of General Internal Medicine | Volume 2
&
April 04-05, 2018 | Miami, USA
International Conference on
Internal Medicine & Practice and Primary Care
International Meeting on
Breast Pathology & Cancer Diagnosis
T
he idea of using the immune system to fight cancer is
over 100 years old (Paul Ehrlich’s “Magic Bullet”). But
immunotherapy in solid tumors (ST) has been disappointing
over the last several decades. A new molecular approach
led to a better understanding of the immune system. Check
point regulation, understanding roles of Tregs, Th1 and Th2,
development of CAR-T cells, as well as regulation of DC and
Macrophages, has led to discovery of immune checkpoint
inhibitors (ICI) and modulators that are currently used in
studies of several STs. Positive studies have led to the US
FDA approval of a few of these compounds. Moreover,
PD-1 / PDL-1, MSI high (and dMMR), MTB are the currently
“best” predictive markers for IO therapy and recently,
Pembrolizumab was approved in ST with this companion
diagnostic marker. Many large clinical trials in many ST and
in all phases are underway (over 1200). We will discuss the
mechanism of action, its impact on solid tumors, and some
of the early results and next generations ICI.
e:
sgluck@celgene.comState of the art and future of IO in solid tumors: Example breast cancer
Stefan Glück
Celgene Corporation, USA